Stephen Doberstein, Ph.D., has been promoted to Senior Vice President, Research & Development and Chief Research & Development Officer; Mary Tagliaferri, M.D., has been promoted to Senior Vice President, Clinical Development and Chief Medical Officer; Jonathan Zalevsky, Ph.D., has been promoted to Senior Vice President, Research and Chief Scientific Officer.
"I am exceptionally pleased to announce today's promotions which highlight the talent, skill set and extensive achievements of our executive team," said
Dr. Zalevsky joined Nektar in
Nektar Therapeutics is a research-based biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco,
Jennifer Ruddock of Nektar Therapeutics
Jodi Sievers of Nektar Therapeutics
News Provided by Acquire Media